Table 1:
Drug-gene pairs with guidelines for use in clinical practice (from the Clinical Pharmacogenetics Implementation Consortium (CPIC) as of spring 2019*)
| Gene | Drugs |
|---|---|
| Pharmacokinetic mechanisms | |
| CYP2B6 | Efavirenz |
| CYP2C19 | Clopidogrel SSRIs, TCAs Voriconazole, proton pump inhibitors* |
| CYP2C9 | Celecoxib* phenytoin warfarin |
| CYP2D6 | codeine, oxycodone, tramadol SSRIs, TCAs ondansetron tamoxifen, atomoxetine* |
| CYP3A5 | tacrolimus |
| DPYD | 5-fluorouracil, capecitabine, tegafur |
| TPMT, NUDT15 | azathioprine, mercaptopurine, thioguanine |
| SLCO1B1 | simvastatin |
| UGT1A1 | atazanavir |
| Pharmacodynamic mechanisms | |
| CFTR | ivacaftor |
| CYP4F2 | warfarin |
| G6PD | rasburicase |
| HLA-B | abacavir allopurinol carbamazepine phenytoin |
| IFNL3 (IL28B) | interferon |
| RYR1, CACNA1S | inhaled anesthetics |
| VKORC1 | warfarin |
Guidelines published or
*
in process
CPIC: Clinical Pharmacogenetics Implementation Consortium (www.cpicpgx.org)
SSRI: selective serotonin uptake inhibitor
TCA: tricyclic antidepressant